is a joint ANR/NSF fundamental research project centered on the exploitation of the unique chemical and physical properties of nanostructured silicon, biocompatible semiconductor, to develop injectable multifunctional nanosystems for the imaging and therapy of cancer.
is running between 2012 and 2015, and involves 4 research institutes in France and 1 university in the US.
Context & Aims
In cancer research
, the development of non invasive local and focal therapies promises to reduce side effects and resistance phenomenon associated with systematic administration of chemotherapy drugs, and to preserve or limit resection of organs with small size tumors.
Photodynamic therapy (PDT), a clinical treatment that combines the use of a sensitizing agent and light to kill cancer cells, is particularly indicated for the selective destruction of small tumours, but photosensitizers in use today display toxic or other side effects that limit their use.
The main objective of SILGLETO2
is to develop photoactive anti-cancer materials with improved PDT quantum yields and low toxicity, based on biodegradable luminescent silicon-based nanostructures, for the local treatment of cancer.
Ultimately, the project aims to demonstrate that the intrinsic physico-chemical properties of optimized silicon nanostructures formulations will provide an efficient, non-toxic, biodegradable and tumor-selective photosensitizer material clinically usable for PDT.
|Start date: 01 December 2012||Duration: 36 months|
|ANR funding: 462 072 Euros||NSF funding: 420 000 Dollars|
|ANR grant n°: 303482 ||NSF grant n°: DMR-1210417 |